<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278186</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-G-H-0909</org_study_id>
    <nct_id>NCT01278186</nct_id>
  </id_info>
  <brief_title>Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions</brief_title>
  <acronym>BABILON</acronym>
  <official_title>Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B.Braun Surgical SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Infanta Cristina de Badajoz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>B.Braun Surgical SA</source>
  <brief_summary>
    <textblock>
      This study in bifurcated coronary lesions compares the new technology of the
      paclitaxel-eluting balloon with the usual technique until now of &quot;provisional stenting&quot; with
      the paclitaxel-eluting stent in the main branch.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bifurcated coronary lesions are still a challenge for interventional cardiologists, since
      there is no suitable technique or strategy to manage such lesions.

      This multicenter randomized prospective trial in bifurcated coronary lesions will compare the
      new technology of the paclitaxel-eluting balloon with the until now &quot;gold standard&quot; technique
      of the &quot;provisional stenting&quot; with the paclitaxel DES in the main branch.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss (LLL)</measure>
    <time_frame>Late angiographic follow-up (9 months)</time_frame>
    <description>Assessment of the difference between both groups regarding the Late Lumen Loss (LLL) in main vessel and side branch, measured at late angiographic follow-up at 9 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Restenosis</measure>
    <time_frame>Late angiographic follow-up (9 months)</time_frame>
    <description>Assessment of the difference between both groups regarding the Restenosis in both branches (proximal part of the main vessel, distal part of the main vessel and side branch), measured at late angiographic follow-up at 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombosis rate</measure>
    <time_frame>Late angiographic follow-up (9 months)</time_frame>
    <description>Assesment of the thrombosis rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>Late angiographic follow-up (9 months)</time_frame>
    <description>Assessment of the Target Lesion Revascularization (TLR) at late angiographic follow-up (9 months) if dilatation by restenosis or previous angiography due to angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Late angiographic follow-up (9 months)</time_frame>
    <description>Assessment of the rate of Major Adverse Cardiac Events (MACE): death, AMI, Target Lesion Revascularization (TLR) - due to angina pectoris or angiographic restenosis-</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Balloon angioplasty</intervention_name>
    <description>Coronary angioplasty using the paclitaxel-coated balloon catheter</description>
    <arm_group_label>Paclitaxel-eluting balloon</arm_group_label>
    <other_name>SeQuent Please</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stent implantation</intervention_name>
    <description>Coronary angioplasty using the paclitaxel-eluting stent</description>
    <arm_group_label>Paclitaxel-eluting stent</arm_group_label>
    <other_name>Paclitaxel-eluting stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        PATIENTS

          -  Patients with stable angina (1-3) or unstable angina (1-3 A-C) or documented silent
             ischemia

          -  Patients with mental and logistic conditions for the follow-up

          -  Patients should accept an angiographic follow-up at 9 months, a clinical follow-up at
             3 years and sign the consent

        LESIONS

          -  De-novo lesions in the bifurcations of DA/Diag either CX/OM or CD/DP with diameters in
             the main vessel of 2,5 to 3,8/ 2 to 3,5 and lengths &lt; 22 mm

          -  The left main lesions in bifurcation are also accepted but with another independent
             randomization list (specify at randomization)

          -  The diameter of the stenoses should be &gt;50% in any branch with documented ischemia or
             more than 70% in absence of an ischemia test

          -  Single vessel or multivessel disease

          -  In case of a PTCA of more than one lesion, the non included lesion should be treated
             previously to the included lesion

        Exclusion Criteria:

        PATIENTS

          -  Patients with STEMI &lt; 72 hours

          -  Patients with congestive heart failure or NYHA IV, shock or severe valvular heart
             disease

          -  Patients with short life expectancy, or with problems for platelet antiaggregation

          -  Patients in treatment with hyperthyroidism, in treatment with immunosuppression or
             anticoagulants, or with alcohol or drug addiction

          -  Patients included in other trials

          -  Patients with a stroke 6 months before

          -  Patients with a surgery one week before

          -  Severe renal failure calculated as GF &lt; 30 ml/min &quot;Cockcroft Gault&quot;

          -  Women of childbearing age, with probability to become pregnant during the first year
             of follow-up

        LESIONS

          -  Evidence of important thrombus within the vessel to treat

          -  Patients with another stent previously implanted at â‰¤ 15 mm from the current lesion of
             the study

          -  Lesions affecting bypass

          -  Chronic occlusions to treat

          -  Restenosis in-stent or of a segment in 4 mm close to the target lesion

          -  Severe calcification not totally dilatable with the balloon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Ramon Lopez-Minguez, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Infanta Cristina de Badajoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cadiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol. 2005 Oct 18;46(8):1446-55. Epub 2005 Sep 28. Review.</citation>
    <PMID>16226167</PMID>
  </reference>
  <reference>
    <citation>LefÃ¨vre T, Louvard Y, Morice MC, Dumas P, Loubeyre C, Benslimane A, Premchand RK, Guillard N, PiÃ©chaud JF. Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv. 2000 Mar;49(3):274-83.</citation>
    <PMID>10700058</PMID>
  </reference>
  <reference>
    <citation>Koo BK, Kang HJ, Youn TJ, Chae IH, Choi DJ, Kim HS, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS, Tahk SJ. Physiologic assessment of jailed side branch lesions using fractional flow reserve. J Am Coll Cardiol. 2005 Aug 16;46(4):633-7.</citation>
    <PMID>16098427</PMID>
  </reference>
  <reference>
    <citation>Yamashita T, Nishida T, Adamian MG, Briguori C, Vaghetti M, Corvaja N, Albiero R, Finci L, Di Mario C, Tobis JM, Colombo A. Bifurcation lesions: two stents versus one stent--immediate and follow-up results. J Am Coll Cardiol. 2000 Apr;35(5):1145-51.</citation>
    <PMID>10758954</PMID>
  </reference>
  <reference>
    <citation>Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004 Mar 16;109(10):1244-9. Epub 2004 Feb 23.</citation>
    <PMID>14981005</PMID>
  </reference>
  <reference>
    <citation>Pan M, de Lezo JS, Medina A, Romero M, Segura J, Pavlovic D, Delgado A, Ojeda S, MeliÃ¡n F, Herrador J, UreÃ±a I, Burgos L. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am Heart J. 2004 Nov;148(5):857-64.</citation>
    <PMID>15523318</PMID>
  </reference>
  <reference>
    <citation>Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, Gunnes P, Mannsverk J, Meyerdierks O, Rotevatn S, NiemelÃ¤ M, Kervinen K, Jensen JS, GallÃ¸e A, Nikus K, Vikman S, Ravkilde J, James S, AarÃ¸e J, Ylitalo A, Helqvist S, SjÃ¶gren I, Thayssen P, Virtanen K, Puhakka M, Airaksinen J, Lassen JF, Thuesen L; Nordic PCI Study Group. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation. 2006 Oct 31;114(18):1955-61. Epub 2006 Oct 23.</citation>
    <PMID>17060387</PMID>
  </reference>
  <reference>
    <citation>Hildick-Smith D, The BBC ONE (British Bifurcation Coronary study: Old, New and Evolving strategies). Transcatheter Cardiovascular Therapeutics 2008; Oct 12-17. 2008. Washington DC. TCT 2008</citation>
  </reference>
  <reference>
    <citation>Pan M, SuÃ¡rez de Lezo J, Medina A, Romero M, Delgado A, Segura J, Ojeda S, Pavlovic D, Ariza J, FernÃ¡ndez-DueÃ±as J, Herrador J, UreÃ±a I. [Six-month intravascular ultrasound follow-up of coronary bifurcation lesions treated with rapamycin-eluting stents: technical considerations]. Rev Esp Cardiol. 2005 Nov;58(11):1278-86. Spanish.</citation>
    <PMID>16324581</PMID>
  </reference>
  <reference>
    <citation>SuÃ¡rez de Lezo J, Medina A, MartÃ­n P, Amador C, Delgado A, SuÃ¡rez de Lezo J et al. Hallazgos ultrasÃ³nicos durante el tratamiento percutÃ¡neo de lesiones coronarias en bifurcaciones. Rev Esp Cardiol 2008;61:930-5</citation>
  </reference>
  <reference>
    <citation>Medina A, SuÃ¡rez de Lezo J, Pan M. [A new classification of coronary bifurcation lesions]. Rev Esp Cardiol. 2006 Feb;59(2):183. Spanish.</citation>
    <PMID>16540043</PMID>
  </reference>
  <reference>
    <citation>Dzavik V, Kharbanda R, Ivanov J, Ing DJ, Bui S, Mackie K, Ramsamujh R, Barolet A, Schwartz L, Seidelin PH. Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: importance of the bifurcation angle. Am Heart J. 2006 Oct;152(4):762-9.</citation>
    <PMID>16996856</PMID>
  </reference>
  <reference>
    <citation>Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005 Jun 21;45(12):2088-92.</citation>
    <PMID>15963413</PMID>
  </reference>
  <reference>
    <citation>Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 May 4;293(17):2126-30.</citation>
    <PMID>15870416</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Speck U, Schmitt A, BÃ¶hm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003 Oct 15;42(8):1415-20.</citation>
    <PMID>14563585</PMID>
  </reference>
  <reference>
    <citation>Scheller B, Speck U, Abramjuk C, Bernhardt U, BÃ¶hm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004 Aug 17;110(7):810-4. Epub 2004 Aug 9.</citation>
    <PMID>15302790</PMID>
  </reference>
  <reference>
    <citation>Axel DI, Kunert W, GÃ¶ggelmann C, Oberhoff M, Herdeg C, KÃ¼ttner A, Wild DH, Brehm BR, Riessen R, KÃ¶veker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997 Jul 15;96(2):636-45.</citation>
    <PMID>9244237</PMID>
  </reference>
  <reference>
    <citation>Posa A, Hemetsberger R, Petnehazy O, Petrasi Z, Testor M, Glogar D, GyÃ¶ngyÃ¶si M. Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries. Coron Artery Dis. 2008 Jun;19(4):243-7. doi: 10.1097/MCA.0b013e3283030b26.</citation>
    <PMID>18480668</PMID>
  </reference>
  <reference>
    <citation>Nikol S, Huehns TY, HÃ¶fling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis. 1996 Jun;123(1-2):17-31. Review.</citation>
    <PMID>8782834</PMID>
  </reference>
  <reference>
    <citation>Scheller B. Drug-Eluting Balloons: The B.BRAUN Paclitaxel-Eluting Balloon Program: Device Characteristics, Experimental Findings, and Clinical. Outcomes in Patients with In-Stent Restenosis and for Small Vessels (PEPCAD I and II). Transcatheter Cardiovascular Therapeutics 2008; Oct 12-17</citation>
  </reference>
  <reference>
    <citation>Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, BÃ¶hm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006 Nov 16;355(20):2113-24. Epub 2006 Nov 13.</citation>
    <PMID>17101615</PMID>
  </reference>
  <reference>
    <citation>Additional Ongoing BRAUN Paclitaxel-Eluting Balloon Clinical Trials in Diabetics,Bifurcations and Chronic Total Occlusions (Other PEPCAD Studies). Mathey DG. Transcatheter Cardiovascular Therapeutics 2008;October 12-17, 2008 â€¢ Washington, DC.</citation>
  </reference>
  <reference>
    <citation>Fanggiday JC, Stella PR, Guyomi SH, Doevendans PA. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: the DEBIUT (drug-eluting balloon in bifurcation Utrecht) registry. Catheter Cardiovasc Interv. 2008 Apr 1;71(5):629-35. doi: 10.1002/ccd.21452.</citation>
    <PMID>18360855</PMID>
  </reference>
  <reference>
    <citation>Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, Hosten N, Hamm B, Speck U, Ricke J. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008 Sep 23;118(13):1358-65. doi: 10.1161/CIRCULATIONAHA.107.735985. Epub 2008 Sep 8. Erratum in: Circulation. 2008 Oct 14;118(16):e670.</citation>
    <PMID>18779447</PMID>
  </reference>
  <reference>
    <citation>Ferrerio JL, Cequier A, GÃ³mez JA, Maristany J, FernÃ¡ndez F, GÃ³mez M et al. Contraindicaciones al inicio o interrupciÃ³n precoz de la doble antiagregaciÃ³n en pacientes con indicaciÃ³n de intervencionismo coronario percutÃ¡neo. Rev Esp Cardiol 2007;60 Supl 2:1-192 pag 149.</citation>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary stenosis</keyword>
  <keyword>Bifurcation</keyword>
  <keyword>Drug-eluting balloon</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Angiographic follow-up</keyword>
  <keyword>Late Lumen Loss</keyword>
  <keyword>Restenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

